Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 1–15 of 15 studies in Prevention and risk in JAMA Network Open · free to read · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Prevention and risk” covers

Prevention and risk — What might lower the risk of dementia — and what happened when those things were properly tested.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Physical Activity and Cognitive Decline Among Older Adults: A Systematic Review and Meta-Analysis

✓ Peer-reviewed alzhub usefulness score 80 out of 100. JAMA Network Open 2024-02-05

In this meta-analysis of the association of physical activity with cognitive decline, physical activity was associated with better late-life cognition, but the association was weak. 5 key findings →

Design: meta-analysis Participants: 341,471 Evidence: moderate

A large fraction of dementia cases in the US were associated with potentially modifiable risk factors, especially for Black and Hispanic individuals. 4 key findings →

Design: systematic review Evidence: high

Changes in Alcohol Consumption and Risk of Dementia in a Nationwide Cohort in South Korea

✓ Peer-reviewed alzhub usefulness score 73 out of 100. JAMA Network Open 2023-02-01

In this cohort study of a Korean population, decreased risk of dementia was associated with maintaining mild to moderate alcohol consumption, reducing alcohol consumption from a heavy to a moderate level, and the initiation of mild alcohol consumption, suggesting that the threshold of alcohol consumption for dementia risk reduction is low. 5 key findings →

Design: cohort Participants: 3,933,382 Evidence: moderate

In this cohort study, high adherence to a flavonoid-rich diet score was associated with a lower risk of dementia, with reductions more pronounced in individuals with a high genetic risk, hypertension, and depressive symptoms. 5 key findings →

Design: cohort Participants: 121,986 Evidence: moderate

Burden of Cause-Specific Mortality Associated With PM2.5 Air Pollution in the United States

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA network open 2019-11-01

A cohort of 4 522 160 US veterans (4 243 462 [93.8%] male; median [interquartile range] age, 64.1 [55.7-75.5] years; 3 702 942 [82.0%] white, 667 550 [14.8%] black, and 145 593 [3.2%] other race) was followed up for a median (interquartile range) of 10.0 (6.8-10.2) years. 5 key findings →

Design: cohort study Evidence: moderate

Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA Network Open 2024-07-01

In this cohort and MR study of UK Biobank participants, cataracts were associated with increased risk of dementia, especially vascular dementia, and reduced total brain volumes. 5 key findings →

Design: cohort Participants: 304,953 Evidence: moderate

Fentanyl Test Strip Use and Overdose Risk Reduction Behaviors Among People Who Use Drugs

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA Network Open 2025-05-13

The study included 732 participants (median [IQR] age, 41 [34.0-48.0] years; 369 [50.4%] male; 64 [8.9%] Black or African American, 587 [81.3%] White, and 71 [9.8%] other races); 414 reported baseline FTS use and 318 did not. 5 key findings →

Design: cohort study Participants: 732 Evidence: moderate

Hearing Loss, Brain Structure, Cognition, and Dementia Risk in the Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA Network Open 2025-11-05

Sample 1 included 1656 participants (mean [range] age, 58.1 [29.7-85.6] years; 903 female [54.5%]), and sample 2 included 935 participants (mean [range] age, 67.6 [60.0-85.6] years; 518 female [55.4%]). 4 key findings →

Design: cohort study Participants: 1,656 Evidence: moderate

Adherence to the Mediterranean Diet and Obesity-Linked Cancer Risk in EPIC

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA Network Open 2025-02-25

A total of 450 111 participants were included in the study (mean [SD] age, 51.1 [9.8] years; 70.8% women) and followed up during a median (IQR) time of 14.9 (4.1) years. 5 key findings →

Design: cohort study Participants: 111 Evidence: moderate

Race and Ethnicity, Lifestyle, Diet, and Survival in Patients With Prostate Cancer

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA Network Open 2025-02-26

A total of 2603 men with nonmetastatic PCa (mean [SD] age, 69.6 [7.1] years) were followed up, and 1346 deaths were documented, including 356 (24.6%) from CVD and 197 (14.6%) from PCa. 5 key findings →

Design: cohort study Participants: 2,603 Evidence: moderate

Diet Quality and Dementia Risk in Older Adults With Alzheimer Pathology

✓ Peer-reviewed alzhub usefulness score 60 out of 100. JAMA Network Open 2026-06-01

Over a mean follow-up of 8.4 years (range, Conclusions and relevance This cohort study of older adults found that adherence to a dietary pattern with lower inflammatory potential was associated with lower dementia risk among individuals with AD pathology and broader neurobiological risk. 3 key findings →

Design: cohort Participants: 1,865 Evidence: early

Childhood Lifestyle Behaviors and Mental Health Symptoms in Adolescence

✓ Peer-reviewed alzhub usefulness score 60 out of 100. JAMA Network Open 2025-02-14

Altogether, 187 adolescents (97 boys [51.9%]; mean age, 15.8 [0.4] years) had valid data on self-reported lifestyle behaviors, and 170 adolescents had valid data on device-assessed lifestyle behaviors. 5 key findings →

Design: cohort study Evidence: moderate

Faith-Based Lifestyle Intervention for Diabetes Prevention Among Adults in Bangladesh

✓ Peer-reviewed alzhub usefulness score 52 out of 100. JAMA Network Open 2025-10-20

Of the 799 participants (mean [SD] age, 46.2 [11.6] years; 424 women [53.1%]) randomized, 641 completed the 12-month follow-up and were included in the intention-to-treat analysis: 341 (n = 4 mosques) in the intervention group and 300 (n = 4 mosques) in the control group. 5 key findings →

Participants: 799 Evidence: high

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed